HDGFL2

Across TCGA pan-cancer cohorts, HDGFL2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated HDGFL2 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher HDGFL2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated HDGFL2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

HNSC, LUAD, and PDAC are the cancer types where HDGFL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.473	0.785	<.001	93	view →
LUAD	OS	Median	II,III,IV	1.000	0.433	.005	17	view →
PDAC	OS	Median	IV	0.951	0.381	.006	9	view →
UCEC	DFS	Median	All	0.849	0.945	.026	4	view →
CCRCC	DFS	Quartile	II,III,IV	1.000	0.351	.036	3	view →
GBM	OS	Quartile	All	0.658	0.266	.010	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

HDGFL2–HNSC (DFS)

Open the HNSC breakdown →